glucagon receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-11. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Following the 1494 Treaty of Tordesillas, the land now called Brazil was claimed for the Portuguese Empire on 22 April 1500, with the arrival of the Portuguese fleet commanded by Pedro Álvares Cabral. Along the coast, the Portuguese encountered various Indigenous communities, most of whom spoke languages of the Tupi–Guarani family. Though the first settlement, São Vicente, was founded in 1532, colonization effectively began in 1534, when King John III of Portugal divided the territory into the fifteen private and autonomous captaincies. However, the decentralized and unorganized captaincy system proved unsuccessful, and in 1549 the Portuguese king restructured them into the Governorate General of Brazil in the city of Salvador, which became the capital of a single and centralized Portuguese colony in South America. In the first two centuries of colonization, Indigenous and European groups lived in constant war, establishing opportunistic alliances in order to gain advantages against each other.
If one were to flip a fair coin five times and get heads each time, it would not be any more likely for a sixth flip to come up tails. Phrased another way, after a long and/or unlikely streak of independently random events, the probability of the next event is not influenced by the preceding events. Humans often feel that the underrepresented outcome is more likely, as if it is due to happen. Such thinking may be attributed to the mistaken belief that gambling, or even chance itself, is a fair process that can correct itself in the event of streaks.
=== Multisignature wallet === In contrast to simple cryptocurrency wallets requiring just one party to sign a transaction, multi-sig wallets require multiple parties to sign a transaction. Multisignature wallets are designed to increase security by requiring a predefined threshold of signatures from independent private keys to authorize any transaction.
== Awards and recognition == Pfizer has received various awards and recognitions related to its workplace policies and corporate practices. In the United States, Pfizer earned a 100% score from the Human Rights Campaign (2025) on the Corporate Equality Index for LGBTQ workplace equality and ranked highly in the Hispanic Association on Corporate Responsibility (2024) Corporate Inclusion Index. Pfizer was named a "Best Place to Work for Disability Inclusion" in the Disability Equality Index (2024) and received awards such as Top Diverse Employer, Top Hispanic Employer, and Top Disability-Friendly Company by DiversityComm, Inc. (2024). Other recognitions include being named one of "America's Greatest Workplaces" by Newsweek (2023), Clinical Trials Arena Excellence Awards 2023, inclusion in the top 10 of the "World's Most Admired Companies" by Fortune (2023), and being listed as a Top Employer for Diversity and Best Employer for Women by Forbes (2022). Pfizer was also recognized as a "Best Place to Work" by Glassdoor (2021) and a Top Employer by Science (2021) for its practices during the pandemic.
== Early life and career == Kiggans was born in Tampa, Florida, and graduated from high school in Orlando, Florida. As a high school student, she worked at Walt Disney World. She is an alumna of Boston University. In 1993 and 1994, she taught English in Japan through the JET Programme. She also lived in Japan as a Navy spouse for five years. Kiggans joined the United States Navy in 1993 and was a Navy pilot for ten years, flying H-46 and H-3 helicopters. After serving in the military, Kiggans attended nursing school at Old Dominion University and Vanderbilt University School of Nursing. She is an adult geriatric nurse practitioner at Eastern Virginia Medical School and in private practice.
Sources: en.wikipedia.org
We were of course glad to meet again and became close friends. On my side feelings developed gradually over the next two years. He seemed to have made his mind up much more quickly, however, and became even more keen when, in the autumn of 1910, rumours spread about that I had got engaged to a distant Spanish relative, Don Jaime, the Duke of Madrid. On hearing this, the Archduke came down post haste from his regiment at Brandýs and sought out his grandmother, Archduchess Maria Theresa, who was also my aunt and the natural confidante in such matters. He asked if the rumor was true and when told it was not, he replied, "Well, I had better hurry in any case or she will get engaged to someone else." Archduke Charles traveled to Villa Pianore and asked for Zita's hand and, on 13 June 1911, their engagement was announced at the Austrian court. Zita in later years recalled that after her engagement she had expressed to Charles her worries about the fate of the Austrian Empire and the challenges of the monarchy. Charles and Zita were married at the Schwarzau castle on 21 October 1911. Charles's great-uncle, the 81-year-old Emperor Franz Joseph I, attended the wedding. He was relieved to see an heir make a suitable marriage, and was in good spirits, even leading the toast at the wedding breakfast. Archduchess Zita soon conceived a son, and Otto was born on 20 November 1912. Seven more children followed in the next decade.
This can be very important in future clinical and community settings, as an increase in copper utilization in hospital room equipment could help to greatly reduce the spread of antibiotic-resistant infection and the horizontal gene transfer of this antibiotic resistance.
Classical MHC molecules present epitopes to the TCRs of CD8+ T lymphocytes. Nonclassical molecules (MHC class IB) exhibit limited polymorphism, expression patterns, and presented antigens; this group is subdivided into a group encoded within MHC loci (e.g., HLA-E, -F, -G), as well as those not (e.g., stress ligands such as ULBPs, Rae1, and H60); the antigen/ligand for many of these molecules remain unknown, but they can interact with each of CD8+ T cells, NKT cells, and NK cells. The oldest evolutionary nonclassical MHC class I lineage in humans was deduced to be the lineage that includes the CD1 and PROCR (also known as EPCR) molecules. This lineage may have been established before the origin of tetrapod species. However, the only nonclassical MHC class I lineage for which evidence exists that it was established before the evolutionary separation of Actinopterygii (ray-finned fish) and Sarcopterygii (lobe-finned fish plus tetrapods) is lineage Z of which members are found, together in each species with classical MHC class I, in lungfish and throughout ray-finned fishes; why the Z lineage was well conserved in ray-finned fish but lost in tetrapods is not understood.
culture prefers breasts that are youthful and upright, some cultures venerate women with drooping breasts, indicating mothering and the wisdom of experience. Research conducted at the Victoria University of Wellington showed that breasts are often the first thing men look at, and for a longer time than other body parts. The writers of the study had initially speculated that the reason for this is due to endocrinology with larger breasts indicating higher levels of estrogen and a sign of greater fertility, but the researchers said that "Men may be looking more often at the breasts because they are simply aesthetically pleasing, regardless of the size." Some women report achieving an orgasm from nipple stimulation, but this is rare. Research suggests that the orgasms are genital orgasms, and may also be directly linked to "the genital area of the brain". In these cases, it seems that sensation from the nipples travels to the same part of the brain as sensations from the vagina, clitoris and cervix. Nipple stimulation may trigger uterine contractions, which then produce a sensation in the genital area of the brain.
Sources: en.wikipedia.org
On 2 November 2010, Lions Gate Entertainment secured the North American distribution rights to Dredd. Headey joined the cast as drug-dealer Ma-Ma in January 2011. Judge Dredd creator John Wagner acted as a consultant on the film. In 2012, he confirmed that it was a new adaptation of the comic material and was not a remake of the 1995 adaptation Judge Dredd, which starred Sylvester Stallone.
=== 1996–2000 === On December 31, 1996, Quest Diagnostics became an independent company as a spin-off from Corning. Kenneth W. Freeman was appointed as CEO during this transition. Over the next year, Quest acquired a clinical laboratory division of Branford, Connecticut–based Diagnostic Medical Laboratory, Inc. (DML). Two years later in 1999, Quest added SmithKline Beecham Clinical Laboratories to their subsidiaries; which includes a joint venture ownership with CompuNet Clinical Laboratory. The purchase of SmithKline Beecham also included the lab's medical sample transport airline (ICAO: LBQ, call sign: LABQUEST) originally founded in 1988. In 1997, Quest and Banner Health formed a joint venture creating the Arizona based Sonora Quest laboratory, a business unit of Laboratory Sciences of Arizona. This entity represents the operations of Quest Diagnostics in the Arizona regional market.
CPA started being used in animal experiments around the world to investigate how antiandrogens affected fetal sexual differentiation. The first clinical use of CPA in the treatment of sexual deviance and prostate cancer occurred in 1966. It was first studied in the treatment of androgen-dependent skin and hair symptoms, specifically acne, hirsutism, seborrhea, and scalp hair loss, in 1969. CPA was first approved for medical use in 1973 in Europe under the brand name Androcur. In 1977, a formulation of CPA was introduced for use by intramuscular injection. CPA was first marketed as a birth control pill in 1978 in combination with ethinylestradiol under the brand name Diane. Following phase III clinical trials, CPA was approved for the treatment of prostate cancer in Germany in 1980. CPA became available in Canada as Androcur in 1987, as Androcur Depot in 1990, and as Diane-35 in 1998. Conversely, CPA was never introduced in any form in the United States. This was reportedly due to concerns about breast tumors observed with high-dose pregnane progestogens in beagle dogs as well as concerns about potential teratogenicity in pregnant women. Use of CPA in transgender women, an off-label indication, was reported as early as 1977. The use of CPA in transgender women was well-established by the early 1990s. The history of CPA, including its discovery, development, and marketing, has been reviewed.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.